Drug Profile
Research programme: Huntington's disease therapeutics - Curia/CHDI
Latest Information Update: 13 Oct 2021
Price :
$50
*
At a glance
- Originator AMRI; CHDI
- Developer CHDI; Curia
- Class
- Mechanism of Action Mitogen-activated protein kinase 10 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Huntington's disease
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Huntington's-disease in USA
- 30 Apr 2009 Early research in Huntington's disease in USA (unspecified route)